Indianapolis, Indiana, USA, November 14, 2026
Eli Lilly and Company has announced a comprehensive set of new clinical trial findings, patient-reported outcomes and real-world evidence across its obesity and cardiometabolic treatment portfolio at ObesityWeek 2026, taking place from November 14–17 in Washington, D.C. The presentations feature data from Zepbound (tirzepatide), Foundayo (orforglipron), EloraTZP (eloralintide and tirzepatide combination) and investigational retatrutide. The research highlights the company’s expanding approach to obesity management, focusing not only on weight reduction but also on improving metabolic health, sleep-related breathing disorders, joint pain and patients’ everyday experiences. Among the major findings, Phase 2 results showed that EloraTZP achieved up to 23.3% average body-weight reduction at 48 weeks in adults with obesity or overweight and type 2 diabetes. Meanwhile, Phase 3 retatrutide results demonstrated improvements in obstructive sleep apnea and knee osteoarthritis symptoms. Additional presentations explored adolescent obesity treatment outcomes with Zepbound and patient experiences with Foundayo’s once-daily oral administration. These findings demonstrate Lilly’s continued investment in innovative obesity therapies and its strategy to address the broader health consequences associated with excess body weight.
EloraTZP Demonstrates Significant Weight Loss in Phase 2 Study
One of the key highlights at ObesityWeek 2026 is the latest Phase 2 clinical data for EloraTZP, an investigational combination of eloralintide, a selective amylin receptor agonist, and tirzepatide, a dual GIP and GLP-1 receptor agonist. The study evaluated the combination in adults with obesity or overweight and type 2 diabetes. At 48 weeks, participants receiving EloraTZP achieved up to an average weight reduction of 54.1 pounds (23.3%), from an average baseline weight of 232.4 pounds. The findings also showed that up to 60% of participants no longer met the body mass index criteria for obesity. In addition to weight reduction, EloraTZP demonstrated meaningful improvements in blood glucose control, with average HbA1c reductions reaching 2.9 percentage points. Up to 77% of participants achieved normal blood glucose levels during the study. These results highlight the potential of combining complementary metabolic pathways to improve both body weight and glycaemic outcomes. Lilly also presented patient-reported findings from its eloralintide Phase 2 programme. At 48 weeks, 74% of participants reported fewer food cravings, 52% reported reduced food noise and 41% of participants who consumed alcohol at baseline reported drinking less. These findings provide additional insight into how investigational amylin-based therapies may influence appetite-related behaviours.
Retatrutide and Zepbound Show Benefits Beyond Weight Reduction
Lilly also presented Phase 3 findings from its TRIUMPH clinical programme, evaluating investigational retatrutide in obesity-related complications. Retatrutide is a once-weekly triple hormone receptor agonist targeting GIP, GLP-1 and glucagon receptors. In the TRIUMPH-1 study, retatrutide reduced the apnea-hypopnea index (AHI), a measure of breathing disruptions during sleep, by up to 60.6% at 80 weeks in adults with moderate-to-severe obstructive sleep apnea and obesity or overweight. In TRIUMPH-2, which included participants with type 2 diabetes, AHI reductions reached up to 48.1%. The company also reported improvements in knee osteoarthritis pain. In TRIUMPH-1, pain scores decreased by up to 73.1% at 80 weeks, while TRIUMPH-4 demonstrated reductions of up to 75.8% at 68 weeks. Separately, findings from the SURMOUNT-ADOLESCENTS study showed that Zepbound reduced body mass index by an average of 21.4% at 72 weeks among adolescents aged 12 to under 18 years with obesity. More than half of the participants no longer met the BMI criteria for obesity, alongside reported improvements in physical comfort and body esteem. These results highlight the importance of evaluating obesity therapies through their potential effects on associated health conditions and quality of life.
Foundayo Real-World Evidence Highlights Oral Treatment Convenience
Another important area of Lilly’s presentations focused on Foundayo (orforglipron), an FDA-approved once-daily oral GLP-1 receptor agonist for chronic weight management in eligible adults. Findings from the FOUNDERS real-world evidence survey indicated that 96–98% of participants considered the oral treatment simple, convenient and easy to use, regardless of when or with what they took it. The survey also found that many participants took Foundayo alongside food, beverages or other oral medications, while approximately 40% reported taking it in the evening, afternoon or at bedtime. These findings provide insight into real-world treatment experiences and the practical considerations associated with oral obesity medications. Unlike injectable GLP-1 therapies, Foundayo can be taken once daily without restrictions on food or water intake. Through its broader research programme, Lilly is also investigating how different treatment mechanisms and administration options can address individual patient needs. The ObesityWeek 2026 presentations reinforce Lilly’s commitment to advancing obesity care beyond weight reduction alone, with research spanning metabolic control, sleep health, joint function, appetite regulation and treatment convenience. While several findings involve investigational candidates that require further clinical and regulatory evaluation, the expanding evidence base represents an important development in obesity and cardiometabolic medicine.
Source: Eli Lilly press release



